Abstract: Low power atmospheric pressure inductively coupled thermal plasma sources integrated with a quenching device (cold ICP) for the efficient production of biologically active agents have been recently developed for potential biomedical applications. In the present work, in vitro experiments aimed at assessing the decontamination potential of a cold ICP source were carried out on bacteria typically associated with chronic wounds and designed to represent a realistic wound environment; further in vitro experiments were performed to investigate the effects of plasma-irradiated physiological saline solution on eukaryotic cells viability. A thorough characterization of the plasma source, for what concerns UV radiation and nitric oxide species production as well as the variation of pH in the treated liquid media, was carried out to garner fundamental insights to be correlated with biological experiments.
Introduction
The widespread use of antibiotics has led to emergence of multi-drug resistant organisms especially in healthcare settings. Since bacterial contamination is most common in trauma and burn wound care, patients with extensive burns are particularly susceptible to opportunistic pathogens; the bacterial species most frequently isolated from wounds are Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumanii and Klebsiella pneumoniae. An effective patient treatment by means of antibiotics is not always achievable and this fact prompts to look for new treatment alternatives. Plasmas as a source of reactive species, radicals, UV radiation, heat and charged particles are a promising technology to reduce bacterial load in chronic wounds, as demonstrated by in vitro tests [1] and also clinical trials [2] . In this frame, a low power inductively coupled thermal plasma source integrated with a quenching device (Fig.1) for the efficient production of biologically active agents at atmospheric pressure has been recently developed and patented for potential biomedical applications [3, 4] .
In the field of thermal plasmas, inductively coupled plasma (ICP) torches have been widely used both at laboratory and industrial scale as high-temperature sources in a wide range of applications and in different disciplines, thanks to their unique characteristics: high energy density, high volume, high purity and high scalability. Since the first introduction of these thermal plasma sources in science and technology in 1961 [5] , the range of possible applications has been steadily growing, to include analytical chemistry for elemental analysis, the chemical synthesis and deposition of high purity materials, spheroidization and purification of metallic and ceramic powders, the synthesis of nano-powders, the destruction of waste materials, as well as in aerospace research and re-entry problem simulation. For what concerns its scalability, we can find industrial products and processes based on ICP technology spanning from a power of a few mW in the field of surface modifications of materials for the electronic industry to the MW range for aerospace research and waste treatment, passing through the well-established products for ICP-OES and ICP-MS detection of trace elements, that have a low power ICP torch as the heart of the process.
Going back with our minds to the words of Thomas Reed in his pioneering 1961 work -"It is still too early to say what the capabilities and the limitations of inductive plasma generation are." -in this work, this relatively old technology is intruded for the first time in the field of Plasma Medicine; we introduce a low power ICP torch, supplied by a 1 kW-13.56 MHz power generator and operated with argon/air mixtures, suitably modified with a quenching device to obtain an effective production of biologically active agents, while keeping effluent P-III-10-4 temperature and UV radiation at values compatible with biomedical treatments; also, we evaluate its antibacterial activity and possible associated cytotoxicity on eukaryotic cells in a realistic in vitro model able to represent a typical wound environment. The low power quenched ICP torch concept for treating biological materials lies in the track of other similar projects and sources: in fact, significant steps in the field of Plasma Medicine that deals with healing of chronic and infected wounds have been accomplished in recent years by means of two other plasma sources that cannot be simply framed as "cold atmospheric plasmas": first in time, we have the development of the "Plason" system, which "generates NO from the atmosphere air by the plasmochemical reaction promoted by the high plasma temperature of an electric arc discharge" when rapidly and suitably quenched, providing relatively high NO amount with significant therapeutical effects Experimental studies showed that an intermittent daily exposures of 60 s to NO-containing gas flow (NO dose of 500 ppm) generated by air-plasma unit ''Plason''improves healing of skin wounds in rats. Further, the gas flow treatment shortened the recovery time of both aseptic and purulent wounds by nearly a third [6] .
More recent is the development of a low power microwave torch able to produce a hot plasma in a flow of argon in the core of an air cooled torch: the MicroPlaSter® source [1, 2] : in this case plasma is generated at the tips of the electrodes which are situated 20 mm upstream from the opening of the torch; to fit the case of plasma treatment of chronic wounds the torch's opening is relatively large (tens of mm in diameter) and the temperature of the gas effluent is within the limits of biocompatibility.
Although the mechanisms of the plasma generation for the cold ICP here presented and the abovementioned sources are different from one another, all these systems have in common the generation at atmospheric pressure of a hot plasma which, besides producing biologically active species, interacts with the medium with biocompatible temperatures thanks to properly designed cooling systems. In the present work, three operating conditions, which enable to limit to maximum 40°C the temperature reached by the substrates during plasma treatment, were selected for biological experiments, aimed at evaluating (i) the decontamination potential of the direct plasma treatment, performed both on agar plates and in contaminated physiological saline solution; (ii) the effects on eukaryotic cells viability of the indirect plasma treatment, performed by exposing physiological saline solution to plasma and adding it to cells.
The antimicrobial activity of the cold ICP plasma was evaluated for direct treatment on agar plates for three Gram and Lung Fibroblasts (HEL 299). In order to get deeper insights on the biologically active agents produced by the cold ICP, a thorough investigation of the UV irradiance and nitric oxide reactive species produced by plasma, jointly with the evaluation of the pH variation in physiological saline solution after plasma-irradiation was carried out. Furthermore, the correlations between the values collected from the afore-reported measurements and the results of the biological experiments have been widely discussed.
Discussion of results
In all our experiments the adopted power was 500 W, the Ar central gas 2 slpm and the Ar sheath flow 14 slpm, thus the maximum possible air mass flow rate in the sheath gas was 0.2 slpm; therefore, we performed the experiments adding 0.2 slpm of air in the sheath flow or, as a second experimental condition, adding only 0.1 slpm of air in the sheath flow. With the aim of evaluating the cold ICP suitability for biomedical applications, test for bacterial cells decontamination and eukaryotic cells viability were carried out in a few operating conditions, reported in Table 1 ; these conditions have been selected in order to keep the temperature reached by the substrates after plasma treatment below 40°C. Concerning the direct plasma treatment of bacterial cells both on agar plate (not presented here due to space limitations) and in physiological saline solution, a strong correlation between the results obtained from these experiments (Fig.2) and the UV radiation emitted by plasma was observed; specifically, the higher the value of UV radiation emitted by plasma (reported in Fig. 3 ) the greater the level of bacterial decontamination. Fig. 2 . E. coli (above) and S. aureus (below) mean Log reduction (LogR) as a function of direct treatment time in physiological saline solution for each plasma operating condition.
In particular, the operating condition B, which enables the highest bacterial decontamination, is characterized by an UV irradiance of 93 µW/cm 2 , which is higher than that reported for plasma sources already employed in clinical trials (80 µW/ cm 2 ) [1] . However, it is worth pointing out that a significant decontamination of bacterial cells both on agar plates and in physiological saline solution was accomplished also in operating conditions A and C, which, being characterized by UV radiation of 56 µW/ cm 2 and 43 µW/ cm 2 respectively, fall in the suitable range for biomedical applications; furthermore, for operating conditions A and C, a relevant decontamination of bacteria in physiological saline solution was measured already after 2 min of direct plasma treatment.
Concerning the decontamination of bacterial suspensions, several studies have already demonstrated that plasma discharges operated at the gas-liquid interface can induce a pH variation in the saline solution and, as a consequence, can exert bactericidal effects [7] . Indeed, several physical and chemical processes take place during plasma treatment (direct effects), driven by various reactive species, electric field and UV radiation produced by the plasma discharge; moreover post-discharge chemical reactions can take place in the irradiated liquid after plasma treatment (indirect effects) [8] . Apparently, all these processes, which enable the decontamination of the bacterial solution, go together with by a significant reduction in pH of the irradiated liquid. Fig. 3 . UV irradiance as a function of the axial distance between the orifice of the quenching device and the UV sensor for different operating conditions. In agreement with the reported studies, our results highlight a strong correlation between the decontamination of bacterial cells suspension and the decrease of pH of the saline solution after the plasma irradiation (Fig. 4) . In fact, after just 2 min of plasma treatment at operating conditions A and C, both a relevant decontamination of bacterial cells and a noticeable decrease of pH in the saline solution were observed. To assess the effects on eukaryotic cells viability of chemical reactive species generated during plasma treatment, physiological saline solution irradiated at operating conditions A, B and C for treatment times up to 8 min was added to keratinocytes and fibroblasts (i.e. indirect treatment).
As reported on Fig. 5 , while the viability of keratinocytes (VERO) was high for all the experimented operating conditions, indirect treatments resulted to be well tolerated also by fibroblasts (HEL) at operating conditions C, for all the tested irradiation time, and at A, for an irradiation time up to 4 min.
The observed behaviors of eukaryotic cells viability could be related to the reduction of the pH of the physiological saline solution after plasma treatment, which in turn can be caused by the UV radiation as well as by the reactive species produced by plasma; further studies will be performed to identify the reactive species generated by the interaction between plasma and saline solution, in order to better understand their effects on both bacterial cells decontamination and eukaryotic cells viability.
Nonetheless, it is worth noticing that pH values of 4.21 and 4.17, achieved treating the saline solution at operating conditions A for 4 min and C for 8 min, did not cause any significant reduction in eukaryotic cells viability; these conditions will be further investigated to evaluate their feasibility for biomedical applications. When compared with other plasma systems aimed at disinfection of wounds and dermatological applications, the cold ICP source presented in this work is able to produce a higher concentrations of NO at the biointerphase than the microwave MicroPlaSter® plasma source (few ppm) but a severely lower one than the DC arc based "Plason" source (hundreds of ppm). Because of their importance in infection and inflammation processes further investigations will be performed to tune operating conditions and the design of the quenching device to enhance and control the production of NO species and UV radiation and their delivery down to the substrate with the aim of an overall better efficiency of the system.
Summary and conclusions
An early study investigating the potential of a cold ICP torch for biomedical applications has been presented. Different operating after the considered treatment times were selected with the final aim of: (i) assessing the decontamination potential of the cold ICP source on bacteria typically associated with chronic wounds; (ii) investigating the effects of direct and indirect plasma treatment on viability of eukaryotic cells. In order to garner fundamental insights on the working map of the presented source and to better understand the results of the biological experiments, UV radiation and nitric oxide species produced by the plasma source, as well as the pH of plasma treated saline solution, were measured.
The investigations led to identify two operating conditions, among those evaluated for biological experiments, which, after only 2 min of treatment, enable to achieve a relevant bacterial decontamination both on agar plates and in physiological saline solution, without any noticeable adverse effects on eukaryotic cells viability when indirectly treated with a plasma activated medium. Since the UV radiation emitted by plasma in these operating conditions is significantly below the value of 80 µW/ cm 2 , the authors do not foresee this as a hindrance for the cold ICP use in biomedical applications. The nitric oxide generation and subsistence down to the substrate has to be further investigated, with the aim of enhancing the potential of the cold ICP for applications in the biomedical field.
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